

Access to Medicine Index 2022

Webinar: SRHR Special Report

Anne-Charlotte Douard, Government engagement and policy officer
Amsterdam, Netherlands

About the Foundation

- The Access to Medicine Foundation mobilises healthcare companies to solve chronic issues of availability and affordability, so that more people in low- and middle-income countries (LMICs) can access vital healthcare products.
- Founded in 2005, the Foundation has published its Access to Medicine Index since 2008, and the AMR Benchmark since 2018.
- The Foundation is an independent non-profit organisation and it does not receive any funding from the pharmaceutical industry.



Access to medicine: media coverage



Big pharma not doing enough to improve drug access - analysis



[1/2] A doctor tests a child for malaria at the Ithari-Asheri Hospital in Arusha, Tanzania, May 11, 2016. REUTERS/Katy Migiro/File Photo

LONDON, Nov 15 (Reuters) - Since the pandemic emerged, more top drugmakers have made progress in improving access to medicines in the developing world, but those gains are largely limited to middle-income countries leaving the poorest behind, an analysis has found.

The report, published by the non-profit Access to Medicine Foundation every two years, found that companies are employing strategies including voluntary licensing and building manufacturing capacity to improve access to medicines in low- and middle-income countries, although these advances have limited depth and breadth.



Farmaceutische bedrijven spannen zich meer in voor arme landen, maar allerarmste vaak over hoofd gezien



GSK, J&J and AZ top global drug access index, but foundation says plenty more work needs to be done



More drugmakers are expanding access in poorer countries, but progress continues to lag overall

By Ed Silberman Nov. 16, 2022



For the first time, many of the world's largest pharmaceutical companies are taking concrete steps to widen access to their medicines in low and middle-income countries, but the poorest countries continue to be disproportionately overlooked, according to a new analysis.

All 20 of the drugmakers reviewed now have an access-to-medicine strategy, up from 17 previously, and all but one company has integrated access-to-medicine strategies into their overall corporate strategies. Moreover, 15 companies now have a structured policy in place to create an access plan for each late-stage R&D project in the pipeline, compared to eight drug companies in 2021.



Access plans increasingly part of drugmakers' strategies, says report

November 14, 2022, Updated 08:50 pm IST, Mumbai, November 14

'But planning still remains limited to a handful of companies'

By PT PHOTO DATA

COMMENTS SHARE



Photo Credit: Bogdanhoda

Drugmakers are increasingly working on plans to improve access to some of their upcoming products, says the Access to Medicine Foundation, in its latest report. However, this planning still remains limited to a handful of companies and does not adequately cover low-income countries, it added.



Eine Initiative von Arzneimittelherstellern in Deutschland



Drugs companies must address 'chronic neglect' of women



Swiss pharma giants fall in access to medicine ranking



The Access to Medicine Index is published every two years. This year it looked back at pharma companies' performance in responding to the pandemic. © neoptone / Anthony Arnes



Era Of COVID-19 Has Seen More Companies Move To Address Access To Medicine. Will They Now Go Further?



The 2022 Access to Medicine Index finds that, since the COVID-19 pandemic hit, more pharmaceutical companies stepped up to make some of their products more widely accessible in low- and middle-income countries (LMICs).

If COVID-19 is to be a turning point in global health, the challenge now is for companies to expand access to more of their products - and in a greater number of countries - to reach people across LMICs.

As the world emerges from the worst of the COVID-19 crisis, pharmaceutical companies are now at an important juncture, where lessons learned from the pandemic can prove pivotal in finding solutions to bridge long-standing gaps in access to medicine in LMICs.

The 2022 Access to Medicine Index, published today, shows that more companies have stepped up and moved in the right direction - including some companies that were previously less likely to take action.

For the first time, all 20 companies in scope report an access-to-medicine strategy, with 19 integrating this into their overall corporate strategy.



GSK, J&J, and AZ head this year's access to medicines ranking

Working with global health stakeholders to advance access

access to
medicine
FOUNDATION



Ministry of Foreign Affairs



Ministry of Health, Welfare and Sport

BILL & MELINDA
GATES foundation


THE LEONA M. AND HARRY B.
HELMSLEY
CHARITABLE TRUST



130+ investors managing assets over USD 21 trillion



Encouraging all 20 companies to take action



MISSION

Stimulate and guide essential healthcare companies to bring their products to people in low- and middle-income countries

Identify critical issues
Build consensus on the role of industry in access

CONVENING
POWER

OUTPUT

Perform in-depth analysis of data and provide original insights

RESEARCH REPORTS
Illustrating opportunities for each company to do more, accompanying best practices

DRIVE ACTION

GLOBAL HEALTH ORGANISATIONS

GOVERNMENTS

INVESTORS

THE PUBLIC

CONVENING
POWER

indirect influence

direct influence

indirect influence

global media

INDUSTRY

Improve buy-in and endorsement of access at CEO/Board level


Empower internal access teams

OUTCOME

Companies make progress on their access to medicine policies and practices

IMPACT

More people in low-and middle income countries have access to healthcare products



Access to Medicine Index 2022

What we measure

Scope

COMPANY SCOPE

20 companies

Selected based on a combination of market capitalisation and relevance of pipeline and portfolio for access to medicine

GEOGRAPHIC SCOPE

108 low- and middle-income countries

DISEASE SCOPE

83 diseases, conditions and pathogens

- 23 Communicable Diseases
- 18 Non-Communicable Diseases
- 20 Neglected Tropical Diseases
- 10 Maternal & Neonatal Health Conditions
- 12 Priority Pathogens

PRODUCT TYPE SCOPE

- Medicines, microbicides, preventive vaccines, therapeutic vaccines
- Vector control products, platform technologies, diagnostics
- Contraceptive methods and devices



Analytical framework for the 2022 Index

3 TECHNICAL AREAS	14 PRIORITY TOPICS	Indicators per topic
A GOVERNANCE OF ACCESS 15%	Responsible business practices	4
	Governance and strategy	3
B RESEARCH & DEVELOPMENT 30%	Access planning	3
	Product development	3
	Building R&D capacity	1
C PRODUCT DELIVERY 55%	Equitable access strategies	3
	Intellectual property strategy	3
	Quality and supply	3
	Licensing quality	2
	Product donations	2
	Registration	1
	Inclusive business models	1
	Local manufacturing	1
Health systems strengthening	1	

Access to Medicine Index 2022

Publication overview

Scale & scope



3

KEY FINDINGS

3

TECHNICAL AREAS

20

DETAILED COMPANY REPORT CARDS

19

BEST PRACTICES


3

SPECIAL REPORTS

Access to Medicine Index 2022


Special Report: Sexual & Reproductive Health &
Rights

R&D pipeline is focused on cancer



* 'Other' is defined as projects which follow a different development cycle than R&D projects which target the treatment of a disease, such as a technical lifecycle for devices.


Companies are addressing seven diseases with priority gaps




What's missing?
HSV-2, Contraceptives, pre-eclampsia, syphilis

* There is one diagnostic project in the pipeline targeting both chlamydia and gonorrhoea.


Registration is lacking in low-income countries




Registration in LMICs is lacking, but positive exceptions for some medicines on the EML




Supranational agreements are focused on three SRHR health needs



8 companies engage in supranational procurement



Company engagement in capacity building for SRHR varies across fields



What can be done to improve access to SRHR products?



Tailoring access strategies for more products, in all income groups



Investing in R&D for product gaps relevant to women and girls in LMICs



Engaging in supranational procurement and addressing gaps for NCDs



Increasing the breadth of registration filings, especially across LICs




Working in partnerships to build capacity and strengthen health systems

Access to Medicine Index 2022 Ranking

How the 20 companies compare?

2022 ACCESS TO MEDICINE INDEX – OVERALL RANKING



Feedback for the 2024 Index

Feedback for the 2024 Index

- For **contraceptives**, are there any recommendations for proxy products to understand the demand/need in certain countries?
- Is **local manufacturing** through technology transfer a possible approach to improving local/regional availability of these products?
- In **supranational procurement agreements**, what terms of the agreements are seen as best practice?
- In **capacity-building initiatives** for SRHR, what factors do companies use to assess where their resources are best needed?
- On **registration**, what factors impact the decision to file to register a product in a particular country? Do you feel collaborative registration procedures or proxy country procedures are useful mechanisms for expanding access?

Thank you!

Anne-Charlotte Douard, Government engagement and policy officer

acdouard@accesstomedicinefoundation.org

www.accesstomedicinefoundation.org